Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alan R. Lifson, Waldo H. Belloso, Richard T. Davey, Daniel Duprez, Jose M. Gatell, Jennifer F. Hoy, Eric A. Krum, Ray Nelson, Court Pedersen, George Perez, Richard W. Price, Ronald J. Prineas, Frank S. Rhame, James H. Sampson & John Worley. (2010) Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials. HIV Clinical Trials 11:4, pages 205-219.
Read now
Read now
Alan R. Lifson, Waldo H. Belloso, Cate Carey, Richard T. Davey, Daniel Duprez, Wafaa M. El-Sadr, Jose M. Gatell, Daniela C. Gey, Jennifer F. Hoy, Eric A. Krum, Ray Nelson, Daniel E. Nixon, Nick Paton, Court Pedersen, George Perez, Richard W. Price, Ronald J. Prineas, Frank S. Rhame, James Sampson & John Worley. (2008) Determination of the Underlying Cause of Death in Three Multicenter International HIV Clinical Trials. HIV Clinical Trials 9:3, pages 177-185.
Read now
Read now
Articles from other publishers (14)
Naresh Poondla, Dhatri Madduru, Santosh Kumari Duppala, Suresh Velpula, Vandana Nunia, Simmi Kharb, Somenath Ghatak, Ashwani Kumar Mishra, Sugunakar Vuree, Md Kausar Neyaz & Prashanth Suravajhala. (2021) Cervical cancer in the era of precision medicine: A perspective from developing countries. Advances in Cancer Biology - Metastasis 3, pages 100015.
Crossref
Crossref
Christina Ekenberg, Joanne Reekie, Adrian G. Zucco, Daniel D. Murray, Shweta Sharma, Cameron R. Macpherson, Abdel Babiker, Virginia Kan, H. Clifford Lane, James D. Neaton & Jens D. Lundgren. (2021) The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. AIDS 35:5, pages 783-789.
Crossref
Crossref
Nicole Wyman Engen, Kathy Huppler Hullsiek, Waldo H Belloso, Elizabeth Finley, Fleur Hudson, Eileen Denning, Catherine Carey, Mary Pearson & Jonathan Kagan. (2019) A randomized evaluation of on-site monitoring nested in a multinational randomized trial. Clinical Trials 17:1, pages 3-14.
Crossref
Crossref
Álvaro H Borges, Jacqueline Neuhaus, Shweta Sharma, James D Neaton, Keith Henry, Olga Anagnostou, Teresa Staub, Sean Emery & Jens D Lundgren. (2019) The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. The Journal of Infectious Diseases 219:2, pages 254-263.
Crossref
Crossref
Brian B. Hart, Anna D. Nordell, Jason F. Okulicz, Adrian Palfreeman, Andrzej Horban, Eynat Kedem, Jacqueline Neuhaus, David R. Jacobs, Daniel A. Duprez & James D. Neaton. (2018) Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It?. JAIDS Journal of Acquired Immune Deficiency Syndromes 77:1, pages 1-7.
Crossref
Crossref
Álvaro H. Borges, Jemma L. O'Connor, Andrew N. Phillips, James D. Neaton, Birgit Grund, Jacqueline Neuhaus, Michael J. Vjecha, Alexandra Calmy, Kersten K. Koelsch & Jens D. Lundgren. (2016) Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. Journal of Infectious Diseases 214:3, pages 408-416.
Crossref
Crossref
. (2015) Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine 373:9, pages 795-807.
Crossref
Crossref
Christopher J. Miller, Jason V. Baker, Alison M. Bormann, Kristine M. Erlandson, Katherine Huppler Hullsiek, Amy C. Justice, Jacqueline Neuhaus, Roger Paredes, Kathy Petoumenos, Deborah Wentworth, Alan Winston, Julian Wolfson & James D. Neaton. (2014) Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. PLoS ONE 9:4, pages e95061.
Crossref
Crossref
Abdel G Babiker, Sean Emery, Gerd Fätkenheuer, Fred M Gordin, Birgit Grund, Jens D Lundgren, James D Neaton, Sarah L Pett, Andrew Phillips, Giota Touloumi & Michael J Vjechaj. (2012) Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clinical Trials 10:1_suppl, pages S5-S36.
Crossref
Crossref
Katherine Huppler Hullsiek & Birgit Grund. (2011) Considerations for Endpoint Selection When Designing HIV Clinical Trials. Current Infectious Disease Reports 14:1, pages 110-118.
Crossref
Crossref
E. Fontas, I. Kousignian, C. Pradier, I. Poizot-Martin, C. Durier, L. Weiss, Y. Levy & D. Costagliola. (2010) IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. Journal of Antimicrobial Chemotherapy 65:10, pages 2215-2223.
Crossref
Crossref
Eric Fontas, Isabelle Kousignian, Christian Pradier, Claudine Duvivier, Isabelle Poizot-Martin, Christine Durier, Bernard Jarrousse, Laurence Weiss, Yves Levy & Dominique Costagliola. (2009) Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4. JAIDS Journal of Acquired Immune Deficiency Syndromes 50:2, pages 206-214.
Crossref
Crossref
Letha M. HealeyBarbara K. HahnCatherine A. RehmJoseph AdelsbergerJing QinDean A. FollmannJorge TavelJoseph A. KovacsIrini SeretiRichard T. Davey, Jr.. (2008) The Effect of Continuous Versus Pericycle Antiretroviral Therapy on IL-2 Responsiveness. Journal of Interferon & Cytokine Research 28:7, pages 455-462.
Crossref
Crossref
Michael J Silverberg, Jacqueline Neuhaus, Mark Bower, Daniela Gey, Angelos Hatzakis, Keith Henry, Jose Hidalgo, Leonardo Lourtau, James D Neaton, Giuseppe Tambussi & Donald I Abrams. (2007) Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 21:14, pages 1957-1963.
Crossref
Crossref